Fortis Healthcare
Fortis Healthcare delivered a strong Q3 FY26 with consolidated revenue of ₹2,265 crore (+17.5% YoY) and EBITDA margin expansion of 290 bps to 22.3%, driven by hospital business growth of 19.4% and diagnostics margin r...
Fortis Healthcare vs Eris Lifesciences Q3 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Eris Lifesciences
Eris Lifesciences reported Q1 FY26 consolidated revenue of ₹773 crore (+7.4% YoY) and PAT of ₹125 crore (+41% YoY), driven by strong domestic branded business (DBS) growth of 11% and margin expansion.
Result Snapshot
Revenue₹2,265 Cr₹807 Cr
PAT₹197 Cr₹109 Cr
EBITDA Margin22.3%35%
Sentimentbullishbullish
Key Quotes
Our business performance in Q3 has been good considering the seasonal impact of festivals in some of our key geographies.
We retain our position that we expect to be among the first launches in India post LOE.